Business
Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update
Advances Clinical Pipeline Across Dermatology, Urology, Oncology and strengthens Capital Base to support Phase 2 Programs PHILADELPHIA, PA / ACCESS Newswire /
About this update from Medicus Pharma Ltd.
[{"type":"text","content":"Advances Clinical Pipeline Across Dermatology, Urology, Oncology and strengthens Capital Base to support Phase 2 Programs PHILADELPHIA, PA / ACCESS Newswire / March 25, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) (\"Medicus\" or the \"Company\"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today reported audited financial results for the year ended December 31, 2025, and provided a corporate update highlighting significant progress across its SkinJect® and Teverelix development programs, as well as expansion into precision medicine and AI-enabled clinical development.Management Commentary\"2025 marked a pivotal year for Medicus, highlighted by completion of our Phase 2 SkinJect study, efforts to expand into rare disease and women's health indications, and the integration of agentic AI-driven clinical development capabilities.\" stated Dr. Raza Bokhari. Executive Chairman & CEO of Medicus \"The strength of our clinical dataset, combined with regulatory alignment and potential access to capital resources, positions the Company to advance toward registrational planning and strategic partnerships in 2026 and beyond.\"SkinJect® Platform (Dermatology / Oncology / Rare Disease)SkinJect™, a novel localized immuno-oncology precision product focused on non-melanoma skin diseases, especially basal cell carcinoma (BCC) and Gorlin Syndrome, a rare autosomal dominant disease also called nevoid BCC syndrome, collectively representing an ~$2 billion market opportunity.Skinject Phase 2 Positive Topline Dataset Highlights:The company completed a 90 patient Phase 2 clinical study, titled, \"A randomized, double-blind, three-arm Phase 2 study evaluating two dose levels of microneedle-mediated delivery of doxorubicin compared with a device-only control in patients with nodular basal cell carcinoma.\"The randomized design of SKNJCT-003, including a device-only active control arm, provides a rigorous framework for evaluating the incremental therapeutic contribution of doxorubicin delivered through the SkinJect microneedle system.The Study positive Topline data demonstrated:Up to 73% clinical clearance in the highest dose cohort (200ug dose)continued biological activity between Day 29 and Day 57, supporting durability of response200 ug cohort at Day 57 sugg...